Targeted Therapy
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
UNION therapeuticsDenmark - Hellerup
1 program1
Donafenib combined with paclitaxel and platinum ± PD-1 antibodyPhase 21 trial
Active Trials
Rigel PharmaceuticalsSOUTH SAN FRANCISCO, CA
1 programOlutasidenibPHASE_2Small Molecule1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
2027
2028
2029
Rigel PharmaceuticalsOlutasidenib
UNION therapeuticsDonafenib combined with paclitaxel and platinum ± PD-1 antibody
Clinical Trials (2)
Total enrollment: 88 patients across 2 trials
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
Start: Sep 2025Est. completion: Jun 202968 patients
Phase 2Recruiting
Donafenib for Recurrent Cervical Cancer
Start: Mar 2022Est. completion: Jun 202420 patients
Phase 2Unknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 88 patients
Small Molecule is the dominant modality (100% of programs)
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.